Srinivas Murthy Mascal Gangadharaiah, MD
Internal Medicine · Kennewick, WANPI 1033488077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 43.3% of the total. 2025 is the largest year on record at $1,778, 2.5 times the $725 reported in 2023. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$238
- Bayer$232
- Otsuka America Pharmaceutical, Inc.$194
- GSK$167
- Novo Nordisk$166
- plus $904 from 15 others
What the payments were for
- Food & beverage$3,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,454 |
| Boehringer Ingelheim | 6 | $238 |
| Bayer | 2 | $232 |
| Otsuka America Pharmaceutical, Inc. | 12 | $194 |
| GSK | 12 | $167 |
| Novo Nordisk | 4 | $166 |
| Viatris Specialty LLC | 8 | $159 |
| AbbVie | 6 | $146 |
| Esperion Therapeutics, Inc. | 5 | $118 |
| Pfizer | 5 | $112 |
| Mylan Specialty L.p. | 4 | $95 |
| Medicomp Inc | 1 | $70 |
| Dexcom, Inc. | 1 | $34 |
| 3b Medical, Inc. | 1 | $30 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Amgen | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,355 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 80 | $67,568 |
| OzempicSemaglutide | 62 | $64,369 |
| JardianceEmpagliflozin | 27 | $40,901 |
| JanuviaSitagliptin Phosphate | 33 | $36,670 |
| TradjentaLinagliptin | 33 | $35,706 |
| EliquisApixaban | 33 | $32,829 |
| Tadalafil | 11 | $24,963 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $14,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,517 |
| TrulicityDulaglutide | 11 | $13,994 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $7,617 |
| XareltoRivaroxaban | 11 | $5,885 |
| Gabapentin | 159 | $2,532 |
| Rosuvastatin Calcium | 147 | $2,398 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $238 | $76,60860 claims |
| AstraZenecaFarxiga | $1,454 | $67,56880 claims |
| Novo NordiskOzempic | $166 | $64,36962 claims |
| PfizerEliquis | $112 | $32,82933 claims |
| GSKTrelegy Ellipta | $167 | $14,51720 claims |
| Lilly USA, LLCTrulicity | $20 | $13,99411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Kennewick
- Nadia ToshaniKennewick$7K
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.